Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation
Journal of Medicinal Chemistry · 24.04.2025 · 68 (8) · 8634-8647
DOI: 10.1021/acs.jmedchem.5c00295 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 09.04.2025. Verfasst von Zhijie Deng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute…. Hauptthemen laut MEDLINE: Proteolysis, Ubiquitin-Protein Ligases, Repressor Proteins, Nuclear Proteins. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, Office of the Director.
Abstract (Originalsprache)
Proteolysis Targeting Chimeras (PROTACs) represent promising therapeutic modalities for degrading disease-causing proteins. However, the development of effective PROTACs has been limited by the availability of suitable E3 ligase ligands. In this study, we demonstrate for the first time that SPOP, an unexplored E3 ligase, can be recruited to degrade target proteins of interest. We developed a bridged PROTAC strategy and successfully discovered a proof-of-concept PROTAC degrader 9 (MS479), which recruits the E3 ligase SPOP by directly binding its substrate GLP as a bridge protein. This approach facilitates the polyubiquitination and subsequent degradation of BRD4/3/2 by the 26S proteasome. 9 effectively reduced the protein level of BRD4 short isoform in a time-, concentration-, GLP-, SPOP-, and ubiquitin-proteasome system (UPS)-dependent manner. Additionally, 9 effectively inhibited the proliferation of colorectal cancer (CRC) cells. Overall, our study expands the limited repertoire of the E3 ligases that can be harnessed for targeted protein degradation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, U…
- Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
ORCID-Profile: Youngeun Lee, Jian Jin
Förderung
- NIH HHS
- NCI NIH HHS
- Office of the Director
Zitieren
APA
Deng, Z., Catlett, J., Lee, Y., Wu, Q., Xu, Z., Xie, L., Chen, X., Xiong, Y., Kaniskan, H. Ü., & Jin, J. (2025). Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation. Journal of Medicinal Chemistry, 68(8), 8634-8647. https://doi.org/10.1021/acs.jmedchem.5c00295
Vancouver
Deng Z, Catlett J, Lee Y, Wu Q, Xu Z, Xie L, et al. Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation. Journal of Medicinal Chemistry. 2025;68(8):8634-8647. doi:10.1021/acs.jmedchem.5c00295
BibTeX
@article{Deng2025,
author = {Deng, Zhijie and Catlett, Jerrel and Lee, Youngeun and Wu, Qiong and Xu, Zhongli and Xie, Ling and Chen, Xian and Xiong, Yan and Kaniskan, H Ümit and Jin, Jian},
title = {Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {8},
pages = {8634--8647},
doi = {10.1021/acs.jmedchem.5c00295}
}
EUVIMED